Ginkgo Bioworks heads into its third-quarter report with an unusual split in its numbers. Wall Street expects the loss per share to shrink dramatically from a year ago, while revenue is forecast to fall by almost half. That gap is the whole story. A company trying to build a platform for programming cells cannot shrink forever, and the stock's sharp rally since the last report suggests the market is willing to believe the contraction is ending. Thursday's release, due after the close on November 5, needs to show that this belief is justified.

Consensus calls for a loss of $0.58 per share on revenue of about $20.5 million. Compared with the same quarter last year, that would be a 60% improvement from a loss of $1.45, alongside a 47% drop from $38.8 million in revenue. The sequential view is more revealing. Last quarter Ginkgo posted $20.2 million in revenue and lost $0.86 per share, so analysts are modeling a top line that is essentially flat while the loss narrows by roughly a third. Put simply, the Street is betting that costs are falling much faster than sales. If the company delivers that, it supports the idea that the business is being resized to fit a smaller revenue base. If the loss improvement comes mostly from one-time items rather than lower operating spending, the progress will look far less durable.

With no fresh formal outlook to anchor estimates, the revenue line carries extra weight. A second straight quarter near $20 million would be the first real evidence that the decline seen over the past year has found a floor. That matters more than a few hundred thousand dollars of upside. A clear sequential increase would strengthen the argument that the platform can attract and keep paying customers, while another step down would undercut the recent rally and raise the question of how low the base can go. Any commentary on new customer programs, the mix of recurring versus project-based work, and the pace of cash consumption will help investors judge whether the cost cuts embedded in estimates are sustainable without hollowing out the business.

The market has already moved ahead of the numbers. Shares have climbed about 37% since the prior report, beating the S&P 500 by roughly 38 percentage points over a period when the broader index slipped slightly. Sentiment has warmed as well, with bullish readings rising to 33% from 23.5% ahead of last quarter's report. That is a meaningful shift, though still well short of outright enthusiasm, which suggests optimism tempered by plenty of lingering skepticism.

The chart reflects that tension. At $12.74, the stock sits comfortably above its 200-day moving average of $8.58, a sign that the longer-term trend has turned. Yet it trades about 30% below the post-earnings peak of $18.22 after a run that also touched $6.47. That range is far wider than the $7.10 to $11.14 band of the prior quarter, a reminder that this stock can swing violently on modest news and that a report confirming or denying the turnaround could produce an outsized reaction in either direction.

The central issue is whether Ginkgo can prove it has stopped shrinking while continuing to cut its losses. A narrower loss paired with stable or rising revenue would validate the rally and the improving mood. A narrower loss built on spending cuts alongside another revenue slide would suggest the company is still managing decline rather than building growth, and the gains of recent months could prove fragile.